Australian company Medlab Clinical (ASX.MDC) has reported positive data from the ongoing observational study of NanaBis that is in development as a non-opioid alternative for the treatment of cancer-induced bone pain.
The study was launched 2020 has now enrolled 432 of a target 2,000 patients (24.2%). Of these patients, 15 per cent experience cancer-related pain with 85 per cent non-cancer-related pain. Almost 60 per cent of patients enrolled to date are women. The average age of study participants ranges from 20 to over 80.
The company said data from the third monitoring report shows patients are averaging a dosage of four sprays of NanaBis per day. This corresponds to a 59.5 per cent reported reduction in pain.
NanaBis is a 1:1 formulation of Delta–9–Tetrahydrocannabinol (THC) and cannabidiol (CBD) that has been optimised via the company’s drug delivery platform NanoCelle.
According to Medlab CEO Dr Sean Hall, “It is significant that the body of evidence on the safety, tolerability and efficacy of NanaBis is growing. We are looking to formally submit our multi-centred Phase III trials protocol to the US, UK and Australian regulatory authorities this calendar year. The confirmation of the performance of our product through these real-world trials encourages us to continue to push ahead aggressively with our ultimate objective of a drug registration for NanaBis.”
Dr Hall continued, “The findings of the OBS study and the consistent results across our clinical trials for NanaBis are highly encouraging, in light of our goal to give cancer patients a more effective alternative to manage pain and to achieve regulatory approval and ensure this is widely available to all patients in need.
“Furthermore, with our new manufacturing agreement with Tasmanian Alkaloids (TasAlk) we are able to ensure sufficient supply to support the study and support the continued strong momentum of enrolment. Lastly, due to recent economies of scale, NanaBis™ is expecting a price reduction in the immediate future.”